Industry commentary – Compulsory licences in Thailand override international patents

1 min read
First Published: 
Mar 2007

Key Learnings contained in this article:

Merck has slashed the price of anti-HIV drug Efavirenz in Thailand, two months after Thailand announced a compulsory licence to manufacture a generic version.

This week, it threatened further compulsory licences against another two products, including Plavix, Sanofi-Aventis’s best-selling blood-thinning drug, a move that is legal under world trade laws yet faces major criticism outside the country.

Mongkol na Songkhala, the senior health ministry beaurocrat leading these patent challenges, says this is the only way he can ensure that he can provide health services to Thailand’s 63 million people, and totally rejects industry arguments that high prices are necessary for R&D investment.

Thailand has been leading the fight against the HIV/AIDS epidemic in Asia, but high drug prices for key HIV/AIDS drug have been a big obstacle, so at one level, Thailand’s move is understandable since it faces a real challenge in treating a large number of HIV-positive patients with drugs that are costly even for rich countries.

The debate over whether innovation is best protected and stimulated by the existing patent regime is an important one. But forcing the issue in Thailand when there is scant evidence of the effectiveness of alternative models could be counter-productive.

We'll deliver straight to your inbox

We take your privacy very seriously and will never share your details with other parties.
You're subscribed! We'll send you a welcome email shortly, keep an eye out and if you don't find it perhaps check the (sometimes over-zealous) spam folder.
Oops! Something went wrong while submitting the form.
Clare Gurton
Share this post

Discover the Power of Communication with Rx

Embark on your medcomms journey with Rx today and experience the difference of working with a world-class medical communications agency.

Child playing in autumn leaves
Copyright Rx Communications Ltd